as of 12-12-2025 3:43pm EST
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.7B | IPO Year: | N/A |
| Target Price: | $39.73 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.90 - $33.34 | Next Earning Date: | 11-05-2025 |
| Revenue: | $70,789,000 | Revenue Growth: | 23340.07% |
| Revenue Growth (this year): | 26477.48% | Revenue Growth (next year): | 6.23% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Director, 10% Owner
Avg Cost/Share
$22.00
Shares
454,545
Total Value
$9,999,990.00
Owned After
3,914,458
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | VRDN | Director, 10% Owner | Oct 23, 2025 | Buy | $22.00 | 454,545 | $9,999,990.00 | 3,914,458 |
See how VRDN stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "VRDN Viridian Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.